Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors

Pfizer logo

Pfizer

Status and phase

Completed
Phase 1

Conditions

Neoplasms
Advanced Solid Tumors
Carcinoma
Cancer
Malignancy

Treatments

Biological: CVX-060

Study type

Interventional

Funder types

Industry

Identifiers

NCT00879684
B1131002
CVX-060-101 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to determine the safety and tolerability of CVX-060 in patients with advanced solid tumors.

Enrollment

34 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Confirmed advanced solid tumors unresponsive to currently available therapies or for which there is no standard therapy.
  • Adequate coagulation, liver, and renal function.
  • Candidate for DCE-MRI evaluations.
  • ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1.

Exclusion criteria

  • Evidence of significant bleeding problems.
  • History of certain gastrointestinal problems including fistula and abscess.
  • Chronic, uncontrolled hypertension.
  • Patients with any history of primary or metastatic tumor involvement of the brain or with tumors that encase great vessels.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

34 participants in 1 patient group

1
Experimental group
Treatment:
Biological: CVX-060

Trial contacts and locations

4

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems